Lambert C J Dorssers

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. ncbi Breast cancer oestrogen independence mediated by BCAR1 or BCAR3 genes is transmitted through mechanisms distinct from the oestrogen receptor signalling pathway or the epidermal growth factor receptor signalling pathway
    Lambert C J Dorssers
    Department of Pathology, Josephine Nefkens Institute, Rotterdam, The Netherlands
    Breast Cancer Res 7:R82-92. 2005
  2. ncbi The prognostic value of BCAR1 in patients with primary breast cancer
    Lambert C J Dorssers
    Department of Pathology, Division of Molecular Biology, Erasmus MC Rotterdam, Rotterdam
    Clin Cancer Res 10:6194-202. 2004
  3. ncbi TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer
    Danielle Meijer
    Department of Pathology, Josephine Nefkens Institute, Erasmus MC, Room Be 432, P O Box 2040, 3000 CA, Rotterdam, The Netherlands
    Breast Cancer Res Treat 113:253-60. 2009
  4. ncbi Selective recruitment of breast cancer anti-estrogen resistance genes and relevance for breast cancer progression and tamoxifen therapy response
    Ton van Agthoven
    Department of Pathology, Josephine Nefkens Institute, Erasmus MC University Medical Center Rotterdam, Be432, Erasmus MC PO Box 2040, 3000 CA Rotterdam, The Netherlands
    Endocr Relat Cancer 17:215-30. 2010
  5. ncbi Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance
    Ton van Agthoven
    Department of Pathology, Cancer Genomics Center, Josephine Nefkens Institute, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    J Clin Oncol 27:542-9. 2009
  6. ncbi Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer
    Maurice P H M Jansen
    Department of Medical Oncology, Erasmus MC, Josephine Nefkens Institute, Rotterdam, The Netherlands
    Breast Cancer Res Treat 116:263-71. 2009
  7. ncbi The substrate domain of BCAR1 is essential for anti-estrogen-resistant proliferation of human breast cancer cells
    Arend Brinkman
    Department of Pathology, Josephine Nefkens Institute, Erasmus MC, University Medical Centter Rotterdam, Be432, P O Box 2040, 3000 CA, Rotterdam, The Netherlands
    Breast Cancer Res Treat 120:401-8. 2010
  8. ncbi Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer
    Danielle Meijer
    Department of Pathology, Josephine Nefkens Institute, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    Endocr Relat Cancer 15:101-11. 2008
  9. ncbi Characterization of BCAR4, a novel oncogene causing endocrine resistance in human breast cancer cells
    Marcia Godinho
    Department of Pathology, Josephine Nefkens Institute, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    J Cell Physiol 226:1741-9. 2011
  10. ncbi Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling
    Maurice P H M Jansen
    Department of Medical Oncology, Erasmus MC/Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Clin Oncol 23:732-40. 2005

Collaborators

Detail Information

Publications22

  1. ncbi Breast cancer oestrogen independence mediated by BCAR1 or BCAR3 genes is transmitted through mechanisms distinct from the oestrogen receptor signalling pathway or the epidermal growth factor receptor signalling pathway
    Lambert C J Dorssers
    Department of Pathology, Josephine Nefkens Institute, Rotterdam, The Netherlands
    Breast Cancer Res 7:R82-92. 2005
    ..The aim of this study was to investigate the growth control mediated by these BCAR genes by gene expression profiling...
  2. ncbi The prognostic value of BCAR1 in patients with primary breast cancer
    Lambert C J Dorssers
    Department of Pathology, Division of Molecular Biology, Erasmus MC Rotterdam, Rotterdam
    Clin Cancer Res 10:6194-202. 2004
    ..Here, we study the prognostic value of quantitative BCAR1 levels in a large series of breast cancer specimens...
  3. ncbi TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer
    Danielle Meijer
    Department of Pathology, Josephine Nefkens Institute, Erasmus MC, Room Be 432, P O Box 2040, 3000 CA, Rotterdam, The Netherlands
    Breast Cancer Res Treat 113:253-60. 2009
    ..Both TSC22D1 and PSAP are associated with clinical outcome and may have a functional role in therapy resistance...
  4. ncbi Selective recruitment of breast cancer anti-estrogen resistance genes and relevance for breast cancer progression and tamoxifen therapy response
    Ton van Agthoven
    Department of Pathology, Josephine Nefkens Institute, Erasmus MC University Medical Center Rotterdam, Be432, Erasmus MC PO Box 2040, 3000 CA Rotterdam, The Netherlands
    Endocr Relat Cancer 17:215-30. 2010
    ....
  5. ncbi Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance
    Ton van Agthoven
    Department of Pathology, Cancer Genomics Center, Josephine Nefkens Institute, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    J Clin Oncol 27:542-9. 2009
    ..Here, we explored whether these BCAR genes provide predictive value for tamoxifen resistance and prognostic information for tumor aggressiveness in breast cancer patients...
  6. ncbi Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer
    Maurice P H M Jansen
    Department of Medical Oncology, Erasmus MC, Josephine Nefkens Institute, Rotterdam, The Netherlands
    Breast Cancer Res Treat 116:263-71. 2009
    ..The aim of this study was to evaluate SIAH2 for its (a) predictive/prognostic value, and (b) functional role in endocrine therapy resistance...
  7. ncbi The substrate domain of BCAR1 is essential for anti-estrogen-resistant proliferation of human breast cancer cells
    Arend Brinkman
    Department of Pathology, Josephine Nefkens Institute, Erasmus MC, University Medical Centter Rotterdam, Be432, P O Box 2040, 3000 CA, Rotterdam, The Netherlands
    Breast Cancer Res Treat 120:401-8. 2010
    ..This information may also help to devise alternative personalized treatment strategies with improved outcome for breast cancer patients...
  8. ncbi Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer
    Danielle Meijer
    Department of Pathology, Josephine Nefkens Institute, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    Endocr Relat Cancer 15:101-11. 2008
    ..In addition, as altered expression of FGF17 causes tamoxifen resistance in vitro, the FGF signaling pathway could be a valuable target in the treatment of breast cancer patients resistant to endocrine treatment...
  9. ncbi Characterization of BCAR4, a novel oncogene causing endocrine resistance in human breast cancer cells
    Marcia Godinho
    Department of Pathology, Josephine Nefkens Institute, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    J Cell Physiol 226:1741-9. 2011
    ..Due to its restricted expression, BCAR4 may be a good target for treating antiestrogen-resistant breast cancer...
  10. ncbi Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling
    Maurice P H M Jansen
    Department of Medical Oncology, Erasmus MC/Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Clin Oncol 23:732-40. 2005
    ..Additional studies are needed to confirm if the predictive signature might allow identification of individual patients who could benefit from other (adjuvant) endocrine therapies...
  11. ncbi Application of a newly developed ELISA for BCAR1 protein for prediction of clinical benefit of tamoxifen therapy in patients with advanced breast cancer
    Lambert C J Dorssers
    Department of Pathology, Division of Molecular Biology, Erasmus MC Rotterdam, Rotterdam, The Netherlands
    Clin Chem 50:1445-7. 2004
  12. ncbi Text-derived concept profiles support assessment of DNA microarray data for acute myeloid leukemia and for androgen receptor stimulation
    Rob Jelier
    Department of Medical Informatics, Erasmus MC University Medical Center, Rotterdam, The Netherlands
    BMC Bioinformatics 8:14. 2007
    ..We assign a weight to each concept in the profile based on a likelihood ratio measure. Gene concept profiles can then be clustered to find related genes and other concepts...
  13. ncbi Functional identification of genes causing estrogen independence of human breast cancer cells
    Ton van Agthoven
    Department of Pathology, Josephine Nefkens Institute, Be 432, Erasmus MC University Medical Center Rotterdam, P O Box 2040, Rotterdam, CA, 3000, The Netherlands
    Breast Cancer Res Treat 114:23-30. 2009
    ....
  14. ncbi Protein pathway activation mapping reveals molecular networks associated with antiestrogen resistance in breast cancer cell lines
    Ton van Agthoven
    Department of Pathology, Josephine Nefkens Institute, Erasmus MC University Medical Center Rotterdam, The Netherlands
    Int J Cancer 131:1998-2007. 2012
    ..Our results show that this model provides insights into the molecular and cellular mechanisms of breast cancer progression and antiestrogen resistance. This knowledge may help the development of novel targeted treatments...
  15. ncbi Functional screen for genes responsible for tamoxifen resistance in human breast cancer cells
    Danielle Meijer
    Department of Pathology, Josephine Nefkens Institute, Erasmus MC University Medical Center, Rotterdam, The Netherlands
    Mol Cancer Res 4:379-86. 2006
    ..We conclude that retroviral transfer of cDNA libraries into human breast cancer cells is an efficient method for identifying genes involved in tamoxifen resistance...
  16. ncbi GO-Mapper: functional analysis of gene expression data using the expression level as a score to evaluate Gene Ontology terms
    Marcel Smid
    Department of Pathology, Josephine Nefkens Institute, Erasmus MC, P.O. Box 1738, 3000DR Rotterdam, The Netherlands
    Bioinformatics 20:2618-25. 2004
    ..We demonstrate that the GO-Mapper allows for interrelating relevant biological functions with the experiments under study. AVAILABILITY: The GO-Mapper application is free of charge available from our website...
  17. ncbi Anni 2.0: a multipurpose text-mining tool for the life sciences
    Rob Jelier
    Department of Medical Informatics, Erasmus MC University Medical Center, Dr, Molewaterplein, Rotterdam, 3015 GE, The Netherlands
    Genome Biol 9:R96. 2008
    ..In this article we illustrate Anni's usability by applying the tool to two use cases: interpretation of a set of differentially expressed genes, and literature-based knowledge discovery...
  18. ncbi Deletion of exons 1a-2 of BRCA1: a rather frequent pathogenic abnormality
    Ans M W van den Ouweland
    Department of Clinical Genetics, Josephine Nefkens Institute, Erasmus Medical Center, Rotterdam, The Netherlands
    Genet Test Mol Biomarkers 13:399-406. 2009
    ..This observation, together with the previously described families with exon 1a-2 deletions of BRCA1, demonstrates that this type of deletions is relatively frequent in breast/ovarian cancer families...
  19. ncbi Venn Mapping: clustering of heterologous microarray data based on the number of co-occurring differentially expressed genes
    Marcel Smid
    Department of Pathology, Josephine Nefkens Institute, Erasmus MC, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands
    Bioinformatics 19:2065-71. 2003
    ..From this information novel biological hypotheses may be addressed. AVAILABILITY: Venn Mapper is freely available on http://www.erasmusmc.nl/gatcplatform. SUPPLEMENTARY INFORMATION: http://www.erasmusmc.nl/gatcplatform/vennmapper.html...
  20. ncbi Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families
    Antoinette Hollestelle
    Department of Medical Oncology, Josephine Nefkens Institute and Daniel den Hoed Cancer Center, Erasmus University Medical Center, Rotterdam, The Netherlands
    Breast Cancer Res Treat 128:79-84. 2011
    ..Importantly, results from the current study suggest that KRAS-variant frequencies might be increased among BRCA1 carriers, but solid proof requires confirmation in a larger cohort of BRCA1 carriers...
  21. ncbi Development of an ELISA for measurement of BCAR1 protein in human breast cancer tissue
    Nicolai Grebenchtchikov
    Department of Chemical Endocrinology, University Medical Center Nijmegen, Nijmegen, The Netherlands
    Clin Chem 50:1356-63. 2004
    ..The assay can be used to confirm and to quantitatively extend previous semiquantitative Western blot data on the prognostic and predictive value of BCAR1 in human breast cancer; it can also be applied for other diseases...
  22. ncbi Differential effects of fibroblast growth factors on expression of genes of the plasminogen activator and insulin-like growth factor systems by human breast fibroblasts
    Anieta M Sieuwerts
    Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek and University Hospital Rotterdam, The Netherlands
    Thromb Haemost 87:674-83. 2002
    ....